## GRAL: GRAIL, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.0% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($77.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia**
- Source: samsung.com | 20251231T150921 | Bullish | Relevance: 100%
- Samsung C&T and Samsung Electronics have announced a strategic collaboration with GRAIL, Inc. to introduce GRAIL's Galleri® multi-cancer early detection test to major Asian markets. Additionally, Samsung C&T and Samsung Electronics will invest $110 million in GRAIL, a healthcare company focused on early cancer detection. This partnership aims to make advanced cancer screening accessible in Asia.

**2. Grail Inc (GRAL) Climbs 380% on Strong Optimism for Cancer Detection Kit**
- Source: Yahoo! Finance Canada | 20260102T002800 | Bullish | Relevance: 100%
- Grail Inc. (NASDAQ:GRAL) saw its stock price surge by 379.5% in 2025, driven by positive analyst ratings and strong confidence in its Galleri early cancer detection test kit. The company secured a strategic partnership with Samsung for Asian market distribution, including a $110 million investment from Samsung. Grail Inc. plans to seek FDA pre-market approval for Galleri in Q1 2026.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 4 |

**Top Holders:**
- Blackrock Inc.: 6.3% (+0.7%)
- Primecap Management : 5.2% (-1.6%)
- CRCM LP: 4.7% (-49.5%)
- Vanguard Group Inc: 4.7% (-4.5%)
- Baker Bros. Advisors: 4.2% (0.0%)

### Key Risks

1. High beta (3.62) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.8%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (7.6x), low leverage (D/E 0.16). Institutional flow bullish (4 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 1.00 |
| 52W Range | $16.56 - $115.76 |
| Short Interest | 13.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -4.6% to -3.0% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.9%) - potential reversal signal. AM_20 at -3.6% indicates price below own 20MA trend. Underperforming sector by 4.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.68x) but short-term weakness (below SMA20). MACD histogram bearish (-0.99), momentum weakening. RSI neutral at 48. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.03% (CS: 14) | Weak |
| RSI_14 | 47.5 | Neutral |
| MACD Histogram | -0.99 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 0.980x | Below |
| vs SMA200 | 1.682x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $88.87
- **Stop Loss:** $77.57 (12.7% risk)
- **Target:** $100.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 127
- **Position Value:** $11,286.49
- **Portfolio %:** 11.29%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-19 (Est: $-2.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-3.27 | $-2.46 | +24.7% |
| 2025Q2 | $-3.56 | $-3.18 | +10.8% |
| 2025Q1 | $-3.80 | $-3.10 | +18.5% |
| 2024Q4 | $-4.97 | $-2.89 | +41.9% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*